Compound 22 (TAAR1 antagonist)

Last updated

Compound 22
Compound 22.svg
Clinical data
Other namesC22
Drug class Trace amine-associated receptor 1 (TAAR1) antagonist; Other unknown actions
Identifiers
  • N-[(2,4-dichlorophenyl)methyl]-1-[4-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C17H16Cl2N4
Molar mass 347.24 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1CNCC2=C(C=C(C=C2)Cl)Cl)CN3C=NC=N3
  • InChI=1S/C17H16Cl2N4/c18-16-6-5-15(17(19)7-16)9-20-8-13-1-3-14(4-2-13)10-23-12-21-11-22-23/h1-7,11-12,20H,8-10H2
  • Key:ZNYUDRCDVDXULZ-UHFFFAOYSA-N

Compound 22 is a low-potency and non-selective trace amine-associated receptor 1 (TAAR1) antagonist that was identified in 2015 and was further studied in animals in 2018. [1] [2] The drug enhances the firing rates of dopaminergic neurons ex vivo and potentiates psychostimulant-induced hyperlocomotion and stereotypy in rodents in vivo . [2] The latter effects are partially or fully independent of the TAAR1 however, with the mechanisms underlying these effects being unknown. [2] Compound 22, along with EPPTB and RTI-7470-44, is one of the only TAAR1 antagonists that has been identified as of 2022. [2] [3]

Contents

Pharmacology

Pharmacodynamics

Actions

Compound 22 is a low-potency antagonist of the trace amine-associated receptor 1 (TAAR1). [2] It has shown significant inhibition of TAAR1 signaling at a concentration of 100 μM in vitro . [2] The drug's IC50 Tooltip half-maximal inhibitory concentration value for TAAR1 antagonism is unknown but is greater than 100 μM. [2]

Compound 22 was also screened for off-target activity at 47  targets at a concentration of 10 μM. [2] The screened targets included monoamine receptors, monoamine transporters, histamine receptors, muscarinic acetylcholine receptors, glutamate receptors, GABA receptors, opioid receptors, and sigma receptors. [2] There were five hits (>50% binding inhibition), which included the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET), as well as the sigma σ1 and σ2 receptors. [2] Its affinities (Ki) were 1,800 nM for the SERT, 1,053 nM for the DAT, 1,902 nM for the NET, 276 nM for the sigma σ1 receptor, and 412 nM for the sigma σ2 receptor. [2] Although compound 22 bound with significant affinity to the DAT, it did not inhibit dopamine reuptake and did not interfere with cocaine-induced dopamine reuptake inhibition at concentrations of up to 100 μM. [2]

Effects

Compound 22 increases the firing rate of dopaminergic neurons in mouse ventral tegmental area (VTA) slices ex vivo similarly to the TAAR1 antagonist EPPTB. [2] It increased the firing rate by 88% at a concentration of 100 μM, whereas EPPTB increased the firing rate by 74% at a concentration of 10 nM. [2]

Compound 22 decreased basal locomotor activity in mice in vivo significantly by 58% at 5 mg/kg and non-significantly by 26% at 30 mg/kg. [2] It was not found to stimulate locomotion at any dose. [2] In subsequent experiments, compound 22 did not significantly affect locomotor activity at 5 or 25 mg/kg in either normal mice or TAAR1 knockout mice. [2]

The drug dose-dependently enhanced amphetamine-induced hyperlocomotion in mice. [2] The increases were 28% at 5 mg/kg, 44% at 15 mg/kg, 57% at 20 mg/kg, and 77% at 30 mg/kg, but no difference at 50 mg/kg. [2] Compound 22 likewise potentiated cocaine-induced hyperlocomotion in mice. [2] The increases were 77% at 5 mg/kg, 84% at 15 mg/kg, and 124% at 25 mg/kg. [2] Compound 22 augmented amphetamine- and cocaine-induced stereotypy as well. [2]

In subsequent experiments, compound 22 potentiated amphetamine-induced hyperlocomotion in normal mice by 44% at a dose of 5 mg/kg but had no significant effect at doses of 2.5 and 15 mg/kg. [2] In TAAR1 knockout mice, compound 22 augmented amphetamine-induced hyperlocomotion by 84% at a dose of 15 mg/kg. [2] The drug dose-dependently potentiated cocaine-induced hyperlocomotion at doses of 5, 15, and 25 mg/kg to similar extents in both normal mice and TAAR1 knockout mice. [2] Similar effects of compound 22 were found for amphetamine- and cocaine-induced stereotypy in normal mice and TAAR1 knockout mice. [2]

On the basis of the preceding findings, it was concluded that compound 22 augments psychostimulant-induced hyperlocomotion in a manner that is partially or fully independent of TAAR1 antagonism. [2] The biological targets and mechanisms of compound 22 mediating these effects are unknown. [2]

Pharmacokinetics

Compound 22 was predicted to have good physicochemical and pharmacokinetic properties and to be able to cross the blood–brain barrier. [2] As an example, its predicted logP is 3.3 to 3.7. [2] [4] In accordance with predictions, compound showed clear centrally mediated effects in rodents, indicating that it indeed crosses the blood–brain barrier. [2]

History

Compound 22 was identified in 2015 by virtual screening of over 3 million compounds at the human TAAR1 in silico followed by experimental evaluation of 42 top candidate compounds at the TAAR1 in vitro . [1] [2] Compound 22 is one of the only TAAR1 antagonists that has been identified as of 2022. [3]

Related Research Articles

<span class="mw-page-title-main">Tryptamine</span> Metabolite of the amino acid tryptophan

Tryptamine is an indolamine metabolite of the essential amino acid tryptophan. The chemical structure is defined by an indole—a fused benzene and pyrrole ring, and a 2-aminoethyl group at the second carbon. The structure of tryptamine is a shared feature of certain aminergic neuromodulators including melatonin, serotonin, bufotenin and psychedelic derivatives such as dimethyltryptamine (DMT), psilocybin, psilocin and others.

<span class="mw-page-title-main">Phentermine</span> Weight loss medication

Phentermine, sold under the brand name Adipex-P among others, is a medication used together with diet and exercise to treat obesity. It is available by itself or as the combination phentermine/topiramate. Phentermine is taken by mouth.

<span class="mw-page-title-main">4-Methylaminorex</span> Group of stereoisomers

4-Methylaminorex is a stimulant drug of the 2-amino-5-aryloxazoline group that was first synthesized in 1960 by McNeil Laboratories. It is also known by its street name "U4Euh" ("Euphoria"). It is banned in many countries as a stimulant. 4-Methylaminorex has effects comparable to methamphetamine but with a longer duration.

<span class="mw-page-title-main">3-Iodothyronamine</span> Chemical compound

3-Iodothyronamine (T1AM) is an endogenous thyronamine. It is a high-affinity ligand of the trace amine-associated receptor 1 (TAAR1). T1AM is the most potent endogenous TAAR1 agonist yet discovered. It is also an agonist of the TAAR2 and TAAR5 with similar potency as for the TAAR1 (all in the case of the human proteins). T1AM is not a ligand of the thyroid hormone receptors. However, it is additionally a ligand of various monoamine and other receptors. For instance, it is a muscarinic acetylcholine receptor antagonist.

<i>N</i>-Methylphenethylamine Chemical compound

N-Methylphenethylamine (NMPEA) is a naturally occurring trace amine neuromodulator in humans that is derived from the trace amine, phenethylamine (PEA). It has been detected in human urine and is produced by phenylethanolamine N-methyltransferase with phenethylamine as a substrate, which significantly increases PEA's effects. PEA breaks down into phenylacetaldehyde which is further broken down into phenylacetic acid by monoamine oxidase. When this is inhibited by monoamine oxidase inhibitors, it allows more of the PEA to be metabolized into nymphetamine (NMPEA) and not wasted on the weaker inactive metabolites.

<span class="mw-page-title-main">Benzofuranylpropylaminopentane</span> Chemical compound

(–)-Benzofuranylpropylaminopentane is an experimental drug related to selegiline which acts as a monoaminergic activity enhancer (MAE). It is orally active in animals.

<span class="mw-page-title-main">Nuciferine</span> Chemical compound

Nuciferine is an alkaloid found within the plants Nymphaea caerulea and Nelumbo nucifera.

<span class="mw-page-title-main">TAAR1</span> Protein-coding gene in the species Homo sapiens

Trace amine-associated receptor 1 (TAAR1) is a trace amine-associated receptor (TAAR) protein that in humans is encoded by the TAAR1 gene.

<span class="mw-page-title-main">3-Methoxytyramine</span> Chemical compound

3-Methoxytyramine (3-MT), also known as 3-methoxy-4-hydroxyphenethylamine, is a human trace amine and the major metabolite of the monoamine neurotransmitter dopamine. It is formed by the introduction of a methyl group to dopamine by the enzyme catechol-O-methyltransferase (COMT). 3-MT can be further metabolized by the enzyme monoamine oxidase (MAO) to form homovanillic acid (HVA), which is then typically excreted in the urine.

<i>para</i>-Chloroamphetamine Chemical compound

para-Chloroamphetamine (PCA), also known as 4-chloroamphetamine (4-CA), is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and serotonergic neurotoxin of the amphetamine family. It is used in scientific research in the study of the serotonin system, as a serotonin releasing agent (SRA) at lower doses to produce serotonergic effects, and as a serotonergic neurotoxin at higher doses to produce long-lasting depletions of serotonin.

<span class="mw-page-title-main">Monoamine releasing agent</span> Class of compounds

A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of one or more monoamine neurotransmitters from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitters and hence enhanced signaling by those neurotransmitters. The monoamine neurotransmitters include serotonin, norepinephrine, and dopamine; MRAs can induce the release of one or more of these neurotransmitters.

<span class="mw-page-title-main">3-Methoxyamphetamine</span> Stimulant drug of the amphetamine class

3-Methoxyamphetamine (3-MA), also known as meta-methoxyamphetamine (MMA), is a monoamine releasing agent (MRA) of the amphetamine family. It is a positional isomer of para-methoxyamphetamine.

<span class="mw-page-title-main">RO5166017</span> Chemical compound

RO5166017, or RO-5166017, is a drug developed by Hoffmann-La Roche which acts as a potent and selective agonist for the trace amine-associated receptor 1 (TAAR1), with no significant activity at other targets. It is a partial agonist or near-full agonist depending on the species.

<span class="mw-page-title-main">EPPTB</span> Chemical compound

EPPTB, also known as RO5212773 or RO-5212773, is a drug developed by Hoffmann-La Roche which acts as a potent and selective antagonist or inverse agonist of the trace amine-associated receptor 1 (TAAR1). The drug was the first selective antagonist developed for the TAAR1. It is a potent agonist of the mouse and rat TAAR1, but is dramatically less potent as an agonist of the human TAAR1. EPPTB has been used in scientific research to demonstrate an important role for TAAR1 in regulation of dopaminergic signaling in the limbic system.

<span class="mw-page-title-main">Locomotor activity</span> Behavioral measure in animals

Locomotor activity is a measure of animal behavior which is employed in scientific research.

<span class="mw-page-title-main">Monoaminergic activity enhancer</span> Class of compounds in the nervous system

Monoaminergic activity enhancers (MAE), also known as catecholaminergic/serotonergic activity enhancers (CAE/SAE), are a class of drugs that enhance the action potential-evoked release of monoamine neurotransmitters in the nervous system. MAEs are distinct from monoamine releasing agents (MRAs) like amphetamine and fenfluramine in that they do not induce the release of monoamines from synaptic vesicles but rather potentiate only nerve impulse propagation-mediated monoamine release. That is, MAEs increase the amounts of monoamine neurotransmitters released by neurons per electrical impulse.

<span class="mw-page-title-main">RO5256390</span> Chemical compound

RO5256390 or RO-5256390 is a drug developed by Hoffmann-La Roche which acts as an agonist for the trace amine associated receptor 1 (TAAR1). It is a full agonist of the rat, cynomolgus monkey, and human TAAR1, but a partial agonist of the mouse TAAR1.

<span class="mw-page-title-main">RO5263397</span> TAAR1 agonist

RO5263397, or RO-5263397, is a trace amine-associated receptor 1 (TAAR1) partial or full agonist which is used in scientific research. It is the most well-studied of all of the synthetic TAAR1 ligands. In addition to its use in research, RO5263397 is or was under development for potential clinical use as a medication.

<span class="mw-page-title-main">RO5203648</span> Pharmaceutical compound

RO5203648 is a trace amine-associated receptor 1 (TAAR1) partial agonist. It is a potent and highly selective partial agonist of both rodent and primate TAAR1. The drug suppresses the effects of psychostimulants like cocaine and methamphetamine. It also produces a variety of other behavioral effects, such as antidepressant-like, antipsychotic-like, and antiaddictive effects. Research with RO5203648 has led to interest in TAAR1 agonists for potential treatment of drug addiction. RO5203648 itself was not developed for potential medical use due to poor expected human pharmacokinetics.

<span class="mw-page-title-main">RO5073012</span> Pharmaceutical compound

RO5073012 is a selective low-efficacy partial agonist of the trace amine-associated receptor 1 (TAAR1) which has been used in scientific research. TAAR1 partial agonists like RO5073012 can have agonist- or antagonist-like effects at the TAAR1 depending on the context and level of TAAR1 signaling.

References

  1. 1 2 Lam VM, Rodríguez D, Zhang T, Koh EJ, Carlsson J, Salahpour A (2015). "Discovery of trace amine-associated receptor 1 ligands by molecular docking screening against a homology model". MedChemComm. 6 (12): 2216–2223. doi:10.1039/C5MD00400D. ISSN   2040-2503.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Lam VM, Mielnik CA, Baimel C, Beerepoot P, Espinoza S, Sukhanov I, et al. (2018). "Behavioral Effects of a Potential Novel TAAR1 Antagonist". Front Pharmacol. 9: 953. doi: 10.3389/fphar.2018.00953 . PMC   6131539 . PMID   30233365.
  3. 1 2 Decker AM, Brackeen MF, Mohammadkhani A, Kormos CM, Hesk D, Borgland SL, et al. (April 2022). "Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist". ACS Chem Neurosci. 13 (7): 1082–1095. doi:10.1021/acschemneuro.2c00086. PMC   9730857 . PMID   35325532.
  4. ↑ "N-[(2,4-dichlorophenyl)methyl]-1-[4-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine". PubChem. U.S. National Library of Medicine. Retrieved 26 January 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.